Abstract
Some of the genetic alterations described in thyroid cancer, such as RET/PTC rearrangements, RAS point mutations and PAX8/PPARγ rearrangements, have also been found in benign lesions. The only exception is the point mutation V600E of BRAF oncogene, which is specific for the malignant histology. For this reason, researchers are seeking new markers expressed only by cancer tissues. Among these, telomerase activity and expression, together with miRNAs expression, have been proposed to be able to distinguish benign from malignant lesions both in tissues and FNAC samples with high specificity.
Keywords: miRNA, molecular diagnosis, telomerase, telomere.
Related Journals
Current Dentistry
Current Traditional Medicine
Adolescent Psychiatry
New Emirates Medical Journal
Current Radiopharmaceuticals
Recent Patents on Anti-Cancer Drug Discovery
Current Medicinal Chemistry - Anti-Cancer Agents
Current Cancer Therapy Reviews
Clinical Cancer Drugs
Anti-Cancer Agents in Medicinal Chemistry
Related Books
Andrology: Current and Future Developments
Male Infertility: An Integrative Manual of Western and Chinese Medicine
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Awake Thoracic Surgery
The Anatomical Foundations of Regional Anesthesia and Acute Pain Medicine Macroanatomy Microanatomy Sonoanatomy Functional anatomy
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents